MacroGenics, Inc. MGNX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +49.07%
- 1 year
- +50.00%
- Open
- 2.37
- Prev close
- 2.38
- Mkt cap
- 152.88M
- Vol
- 1.18M
- Avg vol
- 680.69K
- EPS
- -1.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.24
- High
- 2.44
- Forward P/E
- -1.34
- Beta
- 2.08
- Short ratio
- 7.20
- Inst. own
- 93.63%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.65
- 200-d avg
- 6.55
- 1y target
- 7.38
5D chart
Signals (73)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 4:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:40 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:15 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:05 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| RSI: Overbought | Oct 26, 2:25 PM | 6 days ago |
| RSI: Overbought | Oct 26, 2:15 PM | 6 days ago |
| RSI: Overbought | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
News
6 days ago globenewswire.com
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
-
1 week ago benzinga.com
MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial
Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily…
1 week ago globenewswire.com
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
-
2 weeks ago benzinga.com
MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first…
2 weeks ago globenewswire.com
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
3 weeks ago zacks.com
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
3 weeks ago seekingalpha.com
Stock Picks From Seeking Alpha's September 2026 New Analysts
Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital…
1 month ago globenewswire.com
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of…
1 month ago seekingalpha.com
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
Positive risk/reward with MacroGenics trading at a discount to its $327 million cash position or $5.15/share. Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE),…
2 months ago defenseworld.net
Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX
Bank of America Corp DE increased its stake in shares of MacroGenics, Inc. (NASDAQ: MGNX) by 30.7% during the first quarter, according to its most recent filing with the SEC. The institutional…
2 months ago zacks.com
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
2 months ago fool.com
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
-
2 months ago benzinga.com
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11
B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.
2 months ago zacks.com
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.
-
2 months ago benzinga.com
UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of…
2 months ago globenewswire.com
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
-
2 months ago benzinga.com
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead…
2 months ago globenewswire.com
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
3 months ago defenseworld.net
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Brokerages
Shares of MacroGenics, Inc. (NASDAQ: MGNX - Get Free Report) have been given an average rating of "Hold" by the seven ratings firms that are covering the company, MarketBeat.com reports. One research…
3 months ago seekingalpha.com
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend…
-
3 months ago benzinga.com
MacroGenics Plans To Present Dose Escalation And Preliminary Tumor-Specific Cohort Results At The European Society For Medical Oncology Congress, October 23-27
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the…
3 months ago globenewswire.com
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and…
4 months ago zacks.com
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
4 months ago globenewswire.com
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
-
4 months ago benzinga.com
MacroGenics To Receive $24.5M Milestone From Sanofi Following FDA Approval Of TZIELD Expansion In Type 1 Diabetes
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will…
4 months ago globenewswire.com
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
5 months ago globenewswire.com
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,…
-
5 months ago benzinga.com
Macrogenics Q1 EPS $(0.58) Beats $(0.65) Estimate, Sales $20.775M Beat $15.050M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 9.38 percent. This is a 10.77 percent increase over losses of $(0.65)…
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
5 months ago benzinga.com
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.
-
6 months ago benzinga.com
MacroGenics Enters Into Expanded Royalty Purchase Agreement With Sagard In Exchange For Capped Royalty Interest On Future Global Net Sales Of ZYNYZ
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it entered…
-
6 months ago benzinga.com
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
6 months ago benzinga.com
MacroGenics Says FDA Removes Partial Clinical Hold On Phase 2 LINNET Study Of Lorigerlimab, Investigational, Bispecific DART Molecule That Targets PD-1 And CTLA-4
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers• On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc.…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
7 months ago benzinga.com
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $3 to $4.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 months ago benzinga.com
Why Is MacroGenics Stock Sinking Tuesday?
MacroGenics sees stock decline after FDA places partial clinical hold on Phase 2 LINNET study due to safety concerns.
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
11 months ago benzinga.com
Macrogenics Q3 EPS $0.27 Beats $(0.58) Estimate, Sales $72.839M Beat $14.700M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $(0.58) by 146.31 percent. This is a 70 percent decrease over earnings of $0.90…
-
12 months ago benzinga.com
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $2 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
MacroGenics Forged A ZYNYZ Royalty Purchase Deal With Sagard Healthcare Partners For $70M Upfront Payment, Extending Cash Runway Through First Half Of 2027
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the…
-
1 year ago benzinga.com
4 Analysts Assess Macrogenics: What You Need To Know
4 Analysts Assess Macrogenics: What You Need To Know
-
1 year ago benzinga.com
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3
B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target from $5 to $3.
-
1 year ago benzinga.com
Stifel Maintains Hold on Macrogenics, Lowers Price Target to $5
Stifel analyst Stephen Willey maintains Macrogenics (NASDAQ:MGNX) with a Hold and lowers the price target from $6 to $5.
-
1 year ago benzinga.com
Barclays Maintains Overweight on Macrogenics, Lowers Price Target to $3
Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $8 to $3.